You are about to leave www.astellas.com and enter a third-party website. Astellas is not responsible for the content or services on the third-party website.
Would you like to continue?
Corporate Strategic Plan 2021 (CSP2021) maps our journey to realize our VISION of standing on the forefront of healthcare change to turn innovative science into VALUE for patients. How does Astellas define VALUE? Find out more below.
VALUE creation and delivery will be maximized by pursuing these 4 goals:
We have adopted three Organizational Health Goals (OHG) to foster an internal environment where exceptional execution and performance are cultivated and sustained over time:
Performance Goals enable us to measure successful execution of CSP2021 and indicate our aspirations in financial terms. We define our targets in three key aspects:
To meet our CSP2021 goals, Astellas is pursuing Three Enterprise Priorities:
Sustainable Margin Transformation:
A long-term, continuous approach to improving our organizational effectiveness, costs, and ways of working across the company, setting Astellas up for future growth and transformation
Growth Strategy:
New operating model by brand level to maximize brand performance; Agile ways of working to promote faster decision-making
BOLD Ambition:
Agile R&D model to accelerate from discovery to Proof of Concept (PoC), acquiring new assets, etc.; Strengthening in-house capabilities for clinical trial execution and data-driven decision making
For Astellas to realize our VISION, we work with a ‘Common Definition of VALUE’ to communicate and share our aspirations with diverse stakeholders.
With 'outcomes that matter to patients,' Astellas is committed beyond the safety and efficacy of treatments. We seek to understand and optimize our products, and their subsequent use, to maximize improvements in quality of life (QOL) and to minimize the burdens they create. For 'costs to the healthcare system of delivering those outcomes,' we are looking at the individual costs borne by the patient, the healthcare costs borne by insurance companies and public institutions, as well as the indirect costs and burdens imposed on the patient’s family and care givers.
For example, if a drug proves effective in treating a disease that has conventionally required surgery, the outcome for the patient will be significant. It will not only lessen the physical burden on the patient, but also the mental and lifestyle burdens generally experienced by patients.
These benefits are not limited to the patients alone. They will ripple out across society, from the patient’s families and friends to medical institutions as a whole. With lower hospitalizations and surgeries, these institutions can care for a higher number of patients. Therefore, reducing the denominator in our Common Definition of VALUE equation can affect a positive change across society.
We believe that by placing this concept at the core of our business and adapting it to all divisions and regions, Astellas will be able to make a greater contribution to healthcare.
Corporate Strategic Plan 2021 (CSP2021) is based on this 'VALUE' equation, with an overall aim to increase VALUE for patients and realize our VISION.
*Adapted from “What Is Value in HealthCare?” Porter, M.E. (2010). New England Journal of Medicine
